Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Leases (2022 - 2025)

Historic Current Leases for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Atara Biotherapeutics' Current Leases fell 8569.44% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 8569.44%. This contributed to the annual value of $12.9 million for FY2024, which is 1433.77% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Current Leases is $2.0 million, which was down 8569.44% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Current Leases registered a high of $13.7 million during Q3 2024, and its lowest value of $2.0 million during Q3 2025.
  • For the 4-year period, Atara Biotherapeutics' Current Leases averaged around $10.8 million, with its median value being $12.6 million (2022).
  • Per our database at Business Quant, Atara Biotherapeutics' Current Leases skyrocketed by 1433.77% in 2024 and then crashed by 8569.44% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Current Leases stood at $12.8 million in 2022, then decreased by 12.04% to $11.3 million in 2023, then increased by 14.34% to $12.9 million in 2024, then crashed by 84.84% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.2 million for Q2 2025, and $12.8 million during Q1 2025.